Parkwalk’s focused investment strategy, combined with its highly experienced and deep network of partners, specialist co-investors, industry experts and advisors, allows the team to make relatively rapid investment decisions, and deploy capital efficiently.
Parkwalk’s focused asset class has enabled us to develop strong and trusted relationships over the past 10 years, building a reputation as good people to do business with, and bringing with it the highest quality deal-flow.
We are the most co-invested fund in this asset class and we invest c.£50m per year into the sector.
Parkwalk actively seeks to co-invest with other specialist funds
We have the ability to invest from £250k to £10m per round
Invest from early-stage through to Series C round and beyond
Look to follow our money and invest over multiple rounds
Key Parkwalk investment philosophy
- We are willing to take early stage risk but invest across the spectrum from seed to later stage opportunities
- We seek to invest in flat capital structures with all stakeholders (investors, founders, institutions etc) aligned in the same share class
- We feel that by investing we are showing the founders and management respect for their business plan and vision and we expect this to be reciprocated
- We feel these investments are a team effort between all the stakeholders and that moving forward they should all be treated fairly
- We look to follow our money and will invest over multiple rounds
- We have the ability to invest from £250k to £10m in any one round depending on the stage of the business
Parkwalk Funds invest in dynamic university spin-out companies seeking to commercialise intellectual property and technology. From investing in seed to later stage companies, we help fantastic management teams develop and build world-class successful businesses.
Microsaic is the first, and only company to have successfully miniaturised mass spectrometry through the development of its patented chip-based technologies based on Micro-Electrical-Mechanical Systems (MEMS). This chip-based mass spectrometry technology enables point-of-need detection at any stage in a user’s workflow and allows pharmaceutical and biopharmaceutical industries to achieve process
Eykona is 3D hand-held imaging technology for use as a clinical wound measurement and monitoring system. The technology allows clinicians to measure wounds, accurately and repeatably, helping to improve outcomes, reduce costs and ensure that patients with serious wounds are treated optimally.
PolyProx Therapeutics is a spin out of the Department of Pharmacology at the University of Cambridge, and is based on over a decade of research and intellectual property from Founder, Professor Laura Itzhaki’s laboratory. Professor Itzhaki is joined at PolyProx Therapeutics by serial Cambridge biotech entrepreneurs Kevin Moulder as Chief Operating Officer and Andrew Sandham